Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

726 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors.
Jeong W, Rapisarda A, Park SR, Kinders RJ, Chen A, Melillo G, Turkbey B, Steinberg SM, Choyke P, Doroshow JH, Kummar S. Jeong W, et al. Among authors: park sr. Cancer Chemother Pharmacol. 2014 Feb;73(2):343-8. doi: 10.1007/s00280-013-2362-z. Epub 2013 Nov 30. Cancer Chemother Pharmacol. 2014. PMID: 24292632 Free PMC article. Clinical Trial.
A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas.
Park SR, Speranza G, Piekarz R, Wright JJ, Kinders RJ, Wang L, Pfister T, Trepel JB, Lee MJ, Alarcon S, Steinberg SM, Collins J, Doroshow JH, Kummar S. Park SR, et al. Cancer Chemother Pharmacol. 2013 Apr;71(4):981-90. doi: 10.1007/s00280-013-2091-3. Epub 2013 Feb 13. Cancer Chemother Pharmacol. 2013. PMID: 23404627 Free PMC article. Clinical Trial.
Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors.
Kummar S, Srivastava AK, Navas T, Cecchi F, Lee YH, Bottaro DP, Park SR, Do KT, Jeong W, Johnson BC, Voth AR, Rubinstein L, Wright JJ, Parchment RE, Doroshow JH, Chen AP. Kummar S, et al. Among authors: park sr. Invest New Drugs. 2021 Dec;39(6):1577-1586. doi: 10.1007/s10637-021-01138-x. Epub 2021 Jun 28. Invest New Drugs. 2021. PMID: 34180036 Free PMC article. Clinical Trial.
Structure-Based Development of Novel Spiro-Piperidine ASH1L Inhibitors.
Huang G, Stevens R, Hucek DG, Purohit T, Li S, Miao H, Trost E, Hewett G, Clegg B, Park SR, Rajanayake K, Wen B, Sun D, Cierpicki T, Grembecka J. Huang G, et al. Among authors: park sr. J Med Chem. 2024 Dec 16. doi: 10.1021/acs.jmedchem.4c01673. Online ahead of print. J Med Chem. 2024. PMID: 39680643
Correction: Prognostic Impact of Inflammation-Based Factors in Patients with Esophageal Squamous Cell Carcinoma Achieving Pathological Complete Response After Neoadjuvant Chemoradiotherapy Followed by Surgery.
Kim JY, Yun JK, Kim YH, Park SI, Lee JH, Jung HY, Lee GH, Song HJ, Kim DH, Choi KD, Ahn JY, Kim SB, Cho KJ, Ryu JS, Kim JH, Kang J, Park SR, Kim HR. Kim JY, et al. Among authors: park sr. Ann Surg Oncol. 2024 Dec 11. doi: 10.1245/s10434-024-16679-7. Online ahead of print. Ann Surg Oncol. 2024. PMID: 39661290 No abstract available.
726 results